

Bruce A Mungall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5636632/publications.pdf>

Version: 2024-02-01

36
papers

2,334
citations

201674
27
h-index

345221
36
g-index

36
all docs

36
docs citations

36
times ranked

2363
citing authors

#	ARTICLE	IF	CITATIONS
1	From The Cover: Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10652-10657.	7.1	395
2	Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine. Journal of Virology, 2006, 80, 12293-12302.	3.4	166
3	Receptor Binding, Fusion Inhibition, and Induction of Cross-Reactive Neutralizing Antibodies by a Soluble G Glycoprotein of Hendra Virus. Journal of Virology, 2005, 79, 6690-6702.	3.4	157
4	Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies. Journal of Virology, 2006, 80, 891-899.	3.4	155
5	Henipavirus susceptibility to environmental variables. Virus Research, 2008, 132, 140-144.	2.2	112
6	In vitro evidence for a bacterial pathogenesis of equine laminitis. Veterinary Microbiology, 2001, 79, 209-223.	1.9	92
7	Viral Entry Inhibitors Targeted to the Membrane Site of Action. Journal of Virology, 2010, 84, 6760-6768.	3.4	89
8	Simulating Henipavirus Multicycle Replication in a Screening Assay Leads to Identification of a Promising Candidate for Therapy. Journal of Virology, 2009, 83, 5148-5155.	3.4	80
9	Reassortment and evolution of current human influenza A and B viruses. Virus Research, 2004, 103, 55-60.	2.2	72
10	Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virology Journal, 2005, 2, 57.	3.4	71
11	Characterization of the antiviral and inflammatory responses against Nipah virus in endothelial cells and neurons. Virology, 2010, 404, 78-88.	2.4	69
12	Determination of the henipavirus phosphoprotein gene mRNA editing frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected cells. Journal of General Virology, 2009, 90, 398-404.	2.9	67
13	Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors. PLoS ONE, 2013, 8, e60838.	2.5	67
14	Human Parainfluenza Virus Infection of the Airway Epithelium: Viral Hemagglutinin-Neuraminidase Regulates Fusion Protein Activation and Modulates Infectivity. Journal of Virology, 2009, 83, 6900-6908.	3.4	64
15	Intercontinental Circulation of Human Influenza A(H1N2) Reassortant Viruses during the 2001-2002 Influenza Season. Journal of Infectious Diseases, 2002, 186, 1490-1493.	4.0	58
16	A Novel L-ficolin/Mannose-binding Lectin Chimeric Molecule with Enhanced Activity against Ebola Virus. Journal of Biological Chemistry, 2010, 285, 24729-24739.	3.4	51
17	Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. Influenza and Other Respiratory Viruses, 2018, 12, 383-411.	3.4	50
18	Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Research, 2004, 103, 195-197.	2.2	48

#	ARTICLE	IF	CITATIONS
19	Zymographic analysis of equine laminitis. <i>Histochemistry and Cell Biology</i> , 1999, 112, 0467-0472.	1.7	47
20	Vertical Transmission and Fetal Replication of Nipah Virus in an Experimentally Infected Cat. <i>Journal of Infectious Diseases</i> , 2007, 196, 812-816.	4.0	46
21	Tioman Virus, a Paramyxovirus of Bat Origin, Causes Mild Disease in Pigs and Has a Predilection for Lymphoid Tissues. <i>Journal of Virology</i> , 2008, 82, 565-568.	3.4	42
22	Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. <i>Virology Journal</i> , 2009, 6, 187.	3.4	41
23	Recent progress in henipavirus research. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2007, 30, 287-307.	1.6	40
24	Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. <i>Journal of Virological Methods</i> , 2008, 149, 12-19.	2.1	39
25	Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. <i>Virus Research</i> , 2009, 142, 92-99.	2.2	38
26	Inhibition of Henipavirus infection by RNA interference. <i>Antiviral Research</i> , 2008, 80, 324-331.	4.1	35
27	Kinetic Dependence of Paramyxovirus Entry Inhibition. <i>Journal of Virology</i> , 2009, 83, 6947-6951.	3.4	29
28	Anti-hepatitis B activity of isoquinoline alkaloids of plant origin. <i>Archives of Virology</i> , 2014, 159, 1119-1128.	2.1	26
29	<i>Journal of Antivirals & Antiretrovirals</i> . <i>Journal of Antivirals & Antiretrovirals</i> , 2010, 2, 1-10.	0.1	19
30	A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. <i>Expert Review of Vaccines</i> , 2022, 21, 201-214.	4.4	17
31	In situ zymography: topographical considerations. <i>Journal of Proteomics</i> , 2001, 47, 169-176.	2.4	16
32	Ten years of experience with the pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D-conjugate vaccine (Synflorix) in children. <i>Expert Review of Vaccines</i> , 2020, 19, 247-265.	4.4	16
33	A systematic review of the burden of pertussis in South Korea. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1747-1756.	3.3	8
34	A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable <i>Haemophilus influenzae</i> Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 331-345.	2.1	6
35	Response to Wu et al. "Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2675-2680.	3.3	5
36	Letter to the editor to: Isturiz et al. <i>Streptococcus pneumoniae</i> serotype 19A: worldwide epidemiology. <i>Expert review of vaccines</i> 2017;16(10):1007-27. <i>Expert Review of Vaccines</i> , 2018, 17, 665-668.	4.4	1